0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies [Yahoo! Finance]

Amgen Inc. (AMGN)  More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
We recently compiled a list of the 11 Best Kid-Friendly Stocks to Invest In . Amgen Inc. (NASDAQ:AMGN) is one of the best kid-friendly stocks on our list. On March 3, TheFly reported that Kyowa Kirin Co., Ltd. disclosed that it is discontinuing all ongoing clinical trials involving rocatinlimab, an experimental anti-OX40 monoclonal antibody that was previously being tested for moderate-to-severe asthma, prurigo nodularis, and moderate-to-severe atopic dermatitis. The action follows a scheduled safety assessment within the global development program conducted with Amgen Inc. (NASDAQ:AMGN). The latest review highlighted newly emerging safety issues, including additional malignancy cases with potential viral or immune associations, such as confirmed and suspected instances of Kaposi's sarcoma. Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies Although the total number of malignancy events across studies remained below expected background levels, the pattern of th [Read more]
IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
AMGN
NEWS
AMGN
Earnings
AMGN
Analyst Actions
AMGN
SEC Filings
Stockreport

Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies [Yahoo! Finance]

Amgen Inc.  (AMGN) 
More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
We recently compiled a list of the 11 Best Kid-Friendly Stocks to Invest In . Amgen Inc. (NASDAQ:AMGN) is one of the best kid-friendly stocks on our list. On March 3, TheFly reported that Kyowa Kirin Co., Ltd. disclosed that it is discontinuing all ongoing clinical trials involving rocatinlimab, an experimental anti-OX40 monoclonal antibody that was previously being tested for moderate-to-severe asthma, prurigo nodularis, and moderate-to-severe atopic dermatitis. The action follows a scheduled safety assessment within the global development program conducted with Amgen Inc. (NASDAQ:AMGN). The latest review highlighted newly emerging safety issues, including additional malignancy cases with potential viral or immune associations, such as confirmed and suspected instances of Kaposi's sarcoma. Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies Although the total number of malignancy events across studies remained below expected background levels, the pattern of th [Read more]
IMPACT SNAPSHOT
EVENT TIME:
AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS